Sign in to fuzzto save your conversations, follow your research and come back anytime.
Laurus Labs
SectorHealthcare
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs has four manufacturing facilities in Visakhapatnam, Andhra Pradesh, producing APIs, ingredients, and Finished Dosage Formulations (FDFs). The company serves global pharmaceutical markets, particularly in Sub-Saharan Africa, South-East Asia, and Latin America. Laurus Labs also offers contract development and manufacturing services, and produces specialty ingredients for the nutraceutical and cosmeceutical sectors. The company has expanded its operations through acquisitions, partnerships, and investments in new facilities and capabilities.
In the news
Laurus Labs shifts to CDMO business, Nuvama sees 24% upside
Expert Stock Picks: Buy Sun Pharma, Hold HDFC Bank, Sell Laurus Labs
Motilal Oswal's Taparia Recommends 2 Stocks After Market Crash
AI Revolution Drives CDMO Growth as Pharma Innovation Accelerates
Laurus Labs Q1 FY27: CDMO Powerhouse Drives Record Growth
Laurus Labs Sees ₹26.70 Crore Block Trade on NSE at ₹1,108.30 Per Share
The Quarter story
The two most recent quarterly results, compared side-by-side.
Laurus Labs drives consistent revenue and margin expansion, supported by focused manufacturing investment and rising R&D spend.
Consolidated revenue grows from ₹1,570 Cr in Q1 FY26 to ₹2,026 Cr in Q1 2026-27, demonstrating consistent top-line momentum.
Biologics revenue dips from ₹65 Cr in Q4 FY26 to ₹35 Cr in Q1 2026-27, reflecting project cycle volatility.
EBITDA margin expands from 24.8% in Q1 FY26 to 31.8% in Q1 2026-27, confirming sustained pricing power and cost control.
FDF capex share falls from 23% in Q1 FY26 to 6% in Q1 2026-27, signaling strategic reallocation away from finished doses.
API and CDMO capex share rises from 77% in Q1 FY26 to 94% in Q1 2026-27, highlighting focused manufacturing investment.
EU regulatory filings remain flat at 22 from Q1 to Q3 FY26, reflecting stable European engagement without expansion.
Net profit climbs from ₹163 Cr in Q1 FY26 to ₹368 Cr in Q1 2026-27, underscoring strong bottom-line growth.
Canada regulatory filings hold steady at 23 across Q1 to Q3 FY26, indicating consistent regional activity without new submissions.
R&D spend jumps from ₹68 Cr in Q1 FY26 to ₹118 Cr in Q1 2026-27, signaling aggressive innovation investment.
Company insights, generated from the most recent coverage.
Inclusion driven by strong free-float market cap and liquidity, benefiting from global pharmaceutical supply chain diversification trends.
Estimated $598 million passive inflow from MSCI inclusion creates inelastic demand pressure on Aug 31.
Large inflow relative to daily volume may cause price dislocation during closing auction session.